Cancer chemoprevention using natural vitamin D and synthetic analogs

Annual Review of Pharmacology and Toxicology

Volumn 41, Issue , 2001, Pages 421-442

  Guyton, K Z ^a   Kensler, T W ^a   Posner, G H ^a  

^a CCS Associates   (United States)

Author keywords

1 ,25 dihydroxyvitamin D3 analogs; Calcitriol analogs; Deltanoids; Hybrid deltanoids; Noncalcemic deltanoids

Indexed keywords

VITAMIN D; VITAMIN D DERIVATIVE;

APOPTOSIS; CANCER; CANCER PREVENTION; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HYPERCALCEMIA; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; HUMANS; NEOPLASMS; VITAMIN D;

EID: 0035035190     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.41.1.421     Document Type: Review

References (117)

1. Cancer statistics, 2000
2. Perspectives on cancer chemoprevention research and drug development
3. Recent advances in chemoprevention of cancer
4. Perspectives on surrogate endpoints in the development of drugs that reduce the risk of cancer
5. A hearty endorsement for aspirin
6. Approaches to the development and marketing approval of drugs that prevent cancer
7. The vitamin D endocrine system: Manipulation of structure-function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents
8. Vitamin D in the prevention and treatment of prostate cancer
9. Vitamin D and regulation of gene expression
10. 3 receptors: Gene regulation and genetic circuitry
11. Nontranscriptional actions of steroid hormones
12. Skin irritation and cancer in the United States Navy
13. The relation of solar radiation to cancer mortality in North America
14. Do sunlight and vitamin D reduce the likelihood of colon cancer?
15. Geographic variation in breast cancer mortality in the United States: A hypothesis involving exposure to solar radiation
16. Sunlight and breast cancer incidence in the USSR
17. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation
18. Colorectal cancer and solar radiation
19. Calcium and vitamin D. Their potential roles in colon and breast cancer prevention
20. Is vitamin D deficiency a risk factor for prostate cancer?
21. Calcium, vitamin D, and colorectal cancer: A review of the epidemiologic evidence
22. Dietary vitamin D and calcium and risk of colorectal cancer: A 19-year prospective study in men
23. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. The Iowa Women's Health Study
24. Calcium, vitamin D, and dairy foods and the occurrence of colon cancer in men
25. A prospective cohort study of intake of calcium, vitamin D, and other micronutrients in relation to incidence of rectal cancer among postmenopausal women
26. Calcium, vitamin D, and the occurrence of colorectal cancer among women
27. Dietary calcium, vitamin D, and the risk of colorectal cancer in Stockholm, Sweden
28. The association of calcium and vitamin D, and colon and rectal cancer in Wisconsin women
29. Calcium, phosphorus, vitamin D, dairy products and colorectal carcinogenesis: A French case-control study
30. Vitamin D and breast cancer risk: The NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey
31. Vitamin D and prostate cancer: A prediagnostic study with stored sera
32. Prostate cancer and prediagnostic levels of serum vitamin D metabolites
33. Serum vitamin D metabolite levels and the subsequent development of prostate cancer
34. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer
35. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians
36. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans
37. Association of prostate cancer with vitamin D receptor gene polymorphism
38. Calcium, vitamin D, colon cancer
39. 3
40. Influence of dietary calcium and vitamin D on colon epithelial cell proliferation and 1,2-dimethylhydrazine-induced colon carcinogenesis in rats fed high fat diets
41. 3 in chemically induced rat colon carcinogenesis
42. Suppression of colonic carcinogenesis by vitamin D in rats
43. 3 of colon carcinogenesis induced by azoxymethane in Wistar rats
44. The antineoplastic effect of vitamin D in transgenic mice with retinoblastoma
45. 3 of hamster cheek pouch carcinoma induced with 9,10-dimethyl-1,2-benzanthracene with a discussion of the role of intracellular calcium in the development of tumors
46. 3 on N-methyl-N'-nitro-N-nitrosoguanidine-induced gastrointestinal carcinogenesis in Wistar rats
47. 1α,25-Dihydroxyvitamin D3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin
48. 3
49. 3 on tumor promotion in mouse skin
50. 3 agents in murine renal cell carcinoma
51. 3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo
52. 3 in mice
53. Vitamin D, prostate cancer: Biologic interactions and clinical potentials
54. Function relationships in the vitamin D endocrine system
55. EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation-inducing effects on cancer cells
56. 3 analogues with side chains attached to C-18: Synthesis and biological activity
57. The 16-ene vitamin D analogues
58. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia
59. 3
60. Synthesis of C, D-ring modified 1α,25-dihydroxyvitamin D analogues: C-ring analogues
61. Synthesis of C, D-ring modified 1α,25-dihydroxyvitamin D analogs
62. 3 inhibit the growth of human breast cancer cells in vitro and in vivo
63. 5
64. 3 receptor protein
65. 3
66. 3 compounds for use in treatment of disorders involving aberrant activity of hyperproliferative skin, parathyroid, and bone cells
67. 3, a novel vitamin D-related compound with potential therapeutic activity
68. A novel class of vitamin D analogs: Synthesis and preliminary biological evaluation
69. 3 analogues of calcitriol. 1. Synthesis
70. 3: Design, synthesis, and preliminary biological evaluation
71. 5
72. Vitamin D analogs: Perspectives for treatment
73. 3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene
74. 3
75. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate
76. New agents for chemoprevention of prostate cancer
77. 1α,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat
78. 3, inhibits azoxymethane-induced colonic tumorigenesis
79. Clinical counterpoint: Vitamin D: New actions, new analogs, new therapeutic potential
80. 3 analog: Effect on leukemic clonal growth and differentiation, and serum calcium
81. 3 analogs to mice
82. 3 and its synthetic analog, 1α,25-dihydroxy-16-ene-23-yne-26,-27-hexafluoro-19-nor-cholecalciferol (Ro25-6760), on human colon cancer xenograft
83. 3 synthetic analogs inhibit spontaneous metastases in a 1,2-dimethylhydrazine-ineduced colon carcinogenesis model
84. 3. Synthesis and preliminary biological evaluation
85. Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis
86. 3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo
87. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer
88. Toward therapeutic intervention of cancer by vitamin D compounds
89. Vitamin D and regulation of gene expression
90. 3 analogue in rat colonic tumorigenesis
91. Mechanism of action of superactive vitamin D analogs through regulated receptor degradation
92. 3 analogue EB1089 alters receptor complex formation and reduces promoter selectivity
93. 3 receptor
94. 3 receptors by blocking ubiquitin/proteasome-mediated degradation in human skin
95. 3 and its A ring-modified analogs
96. 3 have inhibitory effects on breast cancer cell lines
97. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937
98. kip1 and E-cadherin
99. 3 induction in myeloid leukemic cells
100. 3 in cultured human epidermal keratinocytes
101. 3 reverses the G1 block but not differentiation of HL60 cells
102. Vitamin D analogue EB 1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins
103. 3 analog EB 1089 enhances the response of human breast tumor cells to radiation
104. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53
105. 3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy
106. 3 is a potent inhibitor of tumor cell-induced angiogenesis
107. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma
108. Inhibition of prostate cancer metastasis in vivo: A comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089
109. 1α,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells
110. 3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma
111. 3 or antioestrogen to inhibit T-47D human breast cancer cell proliferation
112. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens